Market Research Logo

Viral Vector & Plasmid DNA Manufacturing Market Analysis Report By Application, By Disease (Cancer, Genetic), By Workflow (Upstream, Downstream), By Vector, By End Use, And Segment Forecasts, 2019 - 2025

Viral Vector & Plasmid DNA Manufacturing Market Analysis Report By Application, By Disease (Cancer, Genetic), By Workflow (Upstream, Downstream), By Vector, By End Use, And Segment Forecasts, 2019 - 2025

The global viral vector & plasmid DNA manufacturing market size is expected to reach USD 882.9 million by 2025, according to a new report by Grand View Research, Inc., rising at a 16.0% CAGR during the forecast period. Rising number of gene therapy-based discovery programs in the pharma industry is one of the key trends driving the production of gene therapy vectors. Moreover, a robust pipeline of viral vaccines and gene therapies has prompted companies to develop novel and effective technologies for scalable manufacturing of vectors. Current vector manufacturing process is considered highly regulated, elaborate, and expensive.

Moreover, at present, there is a shortage of production sites to meet the demand by the pharmaceutical industry for vector construction services. These factors have created opportunities for companies to capitalize on potential avenues in the market through developing novel solutions.

Key growth strategies adopted by companies to sustain their market presence include continuous expansion of manufacturing sites in high-demand markets such as the U.S. and U.K. Moreover, companies are engaged in strategic mergers & facility acquisitions to meet growing requirements of viral vectors within the pharmaceutical and biotech industries and to broaden their service portfolios.

Further Key Findings From the Report Suggest:

  • Adenovirus and retrovirus were prominent vector type segments in the market in 2017. These can be produced at high titers and induce a strong humoral and, especially, a strong T cell response, as a result of which these vector type is extensively employed in vaccines
  • Lentiviral production costs nearly up to 40.0% of the total cost of goods, thus inducing revenue growth in this vector type
  • Downstream processing accounted for the largest share in 2017, owing to requirement of expensive equipment and skilled personnel for product recovery
  • In terms of application, vector manufacturing for antisense, RNAi, & molecular therapy production represented the leading revenue share in 2017. This is due to high adoption rate of viruses for oligonucleotide and aptamers development in comparison to other applications
  • The number of biotech companies that are engaged in employing vector for therapeutic production continue to increase over the period
  • Recent approval of cancer gene therapy products encourages further efforts in this arena, thus resulting in the cancer segment holding the dominant revenue share
  • North America led the global market owing to presence of several universities and research institutes that are engaged in genomic research programs
  • Cobra Biologics, Merck, uniQure N.V., and Novasep are some key participants that are focusing towards capitalizing of untapped avenues in the market.
Please note The report will be updated with the latest data and delivered to you within 3-4 business days.


Chapter 1 Executive Summary
1.1 Market Snapshot
Chapter 2 Research Methodology
2.1 Information Procurement
2.1.1 Purchased Database
2.1.2 GVR’s Internal Database
2.2 Data Analysis
2.3 Market Formulation & Validation
2.4 Approaches for Market Estimation
2.4.1 Approach 1: Commodity Flow & Bottom Up Approach
2.4.2 Approach 2: Top Down and Parent Market Analysis
Chapter 3 Viral Vector & Plasmid DNA Manufacturing Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Robust pipeline for gene therapies and viral vector vaccines
3.1.1.2 Technological advancements for vector production
3.1.1.3 Highly competitive market and various marketing strategies undertaken by the operating entities
3.1.2 Market restraint analysis
3.1.2.1 Regulatory, scientific, and ethical challenges associated with gene therapy
3.1.3 Challenge analysis
3.1.3.1 Production capacity challenges
3.1.3.2 Manufacturing challenges pertaining to the production of vector at large scale
3.1.4 Opportunity analysis
3.1.4.1 Facility expansion for cell and gene therapies
3.1.4.2 Investments, collaboration & partnerships in cell and gene therapies space
3.2 Penetration & Growth Prospect Mapping For Vector Type, 2017
3.3 Viral Vector & Plasmid DNA Manufacturing Market-Swot Analysis, By Factor (Political & Legal, Economic And Technological)
3.4 Industry Analysis - Porter’s
Chapter 4 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Vector Type Estimates & Trend Analysis
4.1 Viral Vector & Plasmid DNA Manufacturing Market: Vector Type Movement Analysis
4.2 Adenovirus
4.2.1 Global adenovirus market, 2014 - 2025 (USD Million)
4.3 Retrovirus
4.3.1 Global retrovirus market, 2014 - 2025 (USD Million)
4.4 Plasmid DNA
4.4.1 Global plasmid DNA market, 2014 - 2025 (USD Million)
4.5 AAV
4.5.1 Global AAV market, 2014 - 2025 (USD Million)
4.6 Lentivirus
4.6.1 Global lentivirus market, 2014 - 2025 (USD Million)
4.7 Other Vectors
4.7.1 Global other vectors market, 2014 - 2025 (USD Million)
Chapter 5 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Workflow Estimates & Trend Analysis
5.1 Viral Vector & Plasmid DNA Manufacturing Market: Workflow Movement Analysis
5.2 Upstream Manufacturing
5.2.1 Global upstream manufacturing market, 2014 - 2025 (USD Million)
5.2.2 Vector amplification & expansion
5.2.2.1 Global vector amplification & expansion market, 2014 - 2025 (USD Million)
5.2.3 Vector recovery/harvesting
5.2.3.1 Global vector recovery/harvesting market, 2014 - 2025 (USD Million)
5.3 Downstream Manufacturing
5.3.1 Global downstream manufacturing market, 2014 - 2025 (USD Million)
5.3.2 Purification
5.3.2.1 Global purification market, 2014 - 2025 (USD Million)
5.3.3 Fill-finish
5.3.3.1 Global fill-finish market, 2014 - 2025 (USD Million)
Chapter 6 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Application Estimates & Trend Analysis
6.1 Viral Vector & Plasmid DNA Manufacturing Market: Application Movement Analysis
6.2 Antisense, RNAi, & Molecular Therapy
6.2.1 Market for antisense, RNAi, & molecular therapy, 2014 - 2025 (USD Million)
6.3 Vaccinology
6.3.1 Market for vaccinology, 2014 - 2025 (USD Million)
Chapter 7 Viral Vector & Plasmid DNA Manufacturing Market Categorization: End-use Estimates & Trend Analysis
7.1 Viral Vector & Plasmid DNA Manufacturing Market: End-use Movement Analysis
7.2 Pharmaceutical and Biopharmaceutical Companies
7.2.1 Market for pharmaceutical and biopharmaceutical companies, 2014 - 2025 (USD Million)
7.3 Research Institutes
7.3.1 Market for research institutes, 2014 - 2025 (USD Million)
Chapter 8 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Disease Estimates & Trend Analysis
8.1 Viral Vector & Plasmid DNA Manufacturing Market: Disease Movement Analysis
8.2 Cancer
8.2.1 Market for cancer, 2014 - 2025 (USD Million)
8.3 Genetic disorders
8.3.1 Market for genetic disorders, 2014 - 2025 (USD Million)
8.4 Infectious diseases
8.4.1 Market for infectious diseases, 2014 - 2025 (USD Million)
8.5 Others
8.5.1 Market for other diseases, 2014 - 2025 (USD Million)
Chapter 9 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Regional Estimates & Trend Analysis
9.1 Viral Vector & Plasmid DNA Manufacturing Market Share By Regional, 2017 & 2025
9.2 North America
9.2.1 Market, 2014 - 2025 (USD Million)
9.2.2 U.S.
9.2.2.1 Market, by vector type, 2014 - 2025 (USD Million)
9.2.2.2 Market, by workflow, 2014 - 2025 (USD Million)
9.2.2.3 Market, by application, 2014 - 2025 (USD Million)
9.2.2.4 Market, by end-use, 2014 - 2025 (USD Million)
9.2.2.5 Market, by disease, 2014 - 2025 (USD Million)
9.2.3 Canada
9.2.3.1 Market, by vector type, 2014 - 2025 (USD Million)
9.2.3.2 Market, by workflow, 2014 - 2025 (USD Million)
9.2.3.3 Market, by application, 2014 - 2025 (USD Million)
9.2.3.4 Market, by end-use, 2014 - 2025 (USD Million)
9.2.3.5 Market, by disease, 2014 - 2025 (USD Million)
9.3 Europe
9.3.1 Market, 2014 - 2025 (USD Million)
9.3.2 Germany
9.3.2.1 Market, by vector type, 2014 - 2025 (USD Million)
9.3.2.2 Market, by workflow, 2014 - 2025 (USD Million)
9.3.2.3 Market, by application, 2014 - 2025 (USD Million)
9.3.2.4 Market, by end-use, 2014 - 2025 (USD Million)
9.3.2.5 Market, by disease, 2014 - 2025 (USD Million)
9.3.3 U.K.
9.3.3.1 Market, by vector type, 2014 - 2025 (USD Million)
9.3.3.2 Market, by workflow, 2014 - 2025 (USD Million)
9.3.3.3 Market, by application, 2014 - 2025 (USD Million)
9.3.3.4 Market, by end-use, 2014 - 2025 (USD Million)
9.3.3.5 Market, by disease, 2014 - 2025 (USD Million)
9.4 Asia Pacific
9.4.1 Market, 2014 - 2025 (USD Million)
9.4.2 Japan
9.4.2.1 Market, by vector type, 2014 - 2025 (USD Million)
9.4.2.2 Market, by workflow, 2014 - 2025 (USD Million)
9.4.2.3 Market, by application, 2014 - 2025 (USD Million)
9.4.2.4 Market, by end-use, 2014 - 2025 (USD Million)
9.4.2.5 Market, by disease, 2014 - 2025 (USD Million)
9.4.3 China
9.4.3.1 Market, by vector type, 2014 - 2025 (USD Million)
9.4.3.2 Market, by workflow, 2014 - 2025 (USD Million)
9.4.3.3 Market, by application, 2014 - 2025 (USD Million)
9.4.3.4 Market, by end-use, 2014 - 2025 (USD Million)
9.4.3.5 Market, by disease, 2014 - 2025 (USD Million)
9.5 Latin America
9.5.1 Market, 2014 - 2025 (USD Million)
9.5.2 Brazil
9.5.2.1 Market, by vector type, 2014 - 2025 (USD Million)
9.5.2.2 Market, by workflow, 2014 - 2025 (USD Million)
9.5.2.3 Market, by application, 2014 - 2025 (USD Million)
9.5.2.4 Market, by end-use, 2014 - 2025 (USD Million)
9.5.2.5 Market, by disease, 2014 - 2025 (USD Million)
9.6 MEA
9.6.1 Market, 2014 - 2025 (USD Million)
9.6.2 South Africa
9.6.2.1 Market, by vector type, 2014 - 2025 (USD Million)
9.6.2.2 Market, by workflow, 2014 - 2025 (USD Million)
9.6.2.3 Market, by application, 2014 - 2025 (USD Million)
9.6.2.4 Market, by end-use, 2014 - 2025 (USD Million)
9.6.2.5 Market, by disease, 2014 - 2025 (USD Million)
Chapter 10 Competitive Landscape
10.1 List of Companies With Portfolio for Vector-based Therapeutic Candidate
10.2 List of Vector Manufacturers
10.3 Strategy Framework
10.4 Market Participation Categorization
10.5 Company Profiles
10.5.1 Merck KGaA
10.5.1.1 Company overview
10.5.1.1.1 Sigma-Aldrich Co. LLC
10.5.1.2 Financial performance
10.5.1.3 Product benchmarking
10.5.1.4 Strategic initiatives
10.5.2 Lonza
10.5.2.1 Company overview
10.5.2.2 Financial performance
10.5.2.3 Product benchmarking
10.5.2.4 Strategic initiatives
10.5.3 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
10.5.3.1 Company overview
10.5.3.2 Financial performance
10.5.3.3 Product benchmarking
10.5.3.4 Strategic initiatives
10.5.4 Cobra Biologics Ltd.
10.5.4.1 Company overview
10.5.4.2 Financial performance
10.5.4.3 Product benchmarking
10.5.4.4 Strategic initiatives
10.5.5 Brammer Bio
10.5.5.1 Company overview
10.5.5.2 Financial performance
10.5.5.3 Product benchmarking
10.5.5.4 Strategic initiatives
10.5.6 Waisman Biomanufacturing
10.5.6.1 Company overview
10.5.6.2 Financial performance
10.5.6.3 Product benchmarking
10.5.6.4 Strategic initiatives
10.5.7 Genezen
10.5.7.1 Company overview
10.5.7.2 Financial performance
10.5.7.3 Product benchmarking
10.5.7.4 Strategic initiatives
10.5.8 YPOSKESI
10.5.8.1 Company overview
10.5.8.2 Financial performance
10.5.8.3 Product benchmarking
10.5.8.4 Strategic initiatives
10.5.9 REGENXBIO, Inc.
10.5.9.1 Company overview
10.5.9.2 Financial performance
10.5.9.3 Product benchmarking
10.5.9.4 Strategic initiatives
10.5.10 Cell and Gene Therapy Catapult
10.5.10.1 Company overview
10.5.10.2 Financial performance
10.5.10.3 Product benchmarking
10.5.10.4 Strategic initiatives
List of Tables
TABLE 1 Clinical trials in cancer gene therapy
TABLE 2 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2014 - 2025 (USD Million)
TABLE 3 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 4 North America upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 5 North America downstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 6 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 7 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2014 - 2025 (USD Million)
TABLE 8 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2014 - 2025 (USD Million)
TABLE 9 U.S. viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2014 - 2025 (USD Million)
TABLE 10 U.S. viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 11 U.S. upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 12 U.S. downstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 13 U.S. viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 14 U.S. viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2014 - 2025 (USD Million)
TABLE 15 U.S. viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2014 - 2025 (USD Million)
TABLE 16 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2014 - 2025 (USD Million)
TABLE 17 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 18 Canada upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 19 Canada downstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 20 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 21 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2014 - 2025 (USD Million)
TABLE 22 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2014 - 2025 (USD Million)
TABLE 23 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2014 - 2025 (USD Million)
TABLE 24 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 25 Europe upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 26 Europe downstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 27 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 28 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2014 - 2025 (USD Million)
TABLE 29 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2014 - 2025 (USD Million)
TABLE 30 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2014 - 2025 (USD Million)
TABLE 31 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 32 Germany upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 33 Germany downstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 34 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 35 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2014 - 2025 (USD Million)
TABLE 36 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2014 - 2025 (USD Million)
TABLE 37 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2014 - 2025 (USD Million)
TABLE 38 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 39 U.K. upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 40 U.K. downstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 41 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 42 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2014 - 2025 (USD Million)
TABLE 43 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2014 - 2025 (USD Million)
TABLE 44 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2014 - 2025 (USD Million)
TABLE 45 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 46 Asia Pacific upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 47 Asia Pacific downstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 48 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 49 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2014 - 2025 (USD Million)
TABLE 50 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2014 - 2025 (USD Million)
TABLE 51 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2014 - 2025 (USD Million)
TABLE 52 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 53 Japan upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 54 Japan downstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 55 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 56 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2014 - 2025 (USD Million)
TABLE 57 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2014 - 2025 (USD Million)
TABLE 58 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2014 - 2025 (USD Million)
TABLE 59 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 60 China upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 61 China downstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 62 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 63 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2014 - 2025 (USD Million)
TABLE 64 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2014 - 2025 (USD Million)
TABLE 65 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2014 - 2025 (USD Million)
TABLE 66 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 67 Latin America upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 68 Latin America downstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 69 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 70 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2014 - 2025 (USD Million)
TABLE 71 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2014 - 2025 (USD Million)
TABLE 72 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2014 - 2025 (USD Million)
TABLE 73 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 74 Brazil upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 75 Brazil downstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 76 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 77 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2014 - 2025 (USD Million)
TABLE 78 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2014 - 2025 (USD Million)
TABLE 79 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2014 - 2025 (USD Million)
TABLE 80 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 81 MEA upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 82 MEA downstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 83 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 84 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2014 - 2025 (USD Million)
TABLE 85 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2014 - 2025 (USD Million)
TABLE 86 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2014 - 2025 (USD Million)
TABLE 87 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 88 South Africa upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 89 South Africa downstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 90 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 91 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2014 - 2025 (USD Million)
TABLE 92 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2014 - 2025 (USD Million)
List of Figures
FIG. 1 Market summary
FIG. 2 Market research process
FIG. 3 Information procurement
FIG. 4 Primary research pattern
FIG. 5 Market research approaches
FIG. 6 Value chain based sizing & forecasting
FIG. 7 QFD modelling for market share assessment
FIG. 8 Market trends & outlook
FIG. 9 Market segmentation & scope
FIG. 10 Market driver relevance analysis (Current & future impact)
FIG. 11 Gene therapies in development (at all stages) per disease group, 2016
FIG. 12 Pipeline analysis for viral vector manufacturing
FIG. 13 Pipeline analysis for viral vector manufacturing
FIG. 14 Pipeline analysis for viral vector manufacturing
FIG. 15 Recent and expected upcoming US/EU approvals for gene transfer-mediated programs
FIG. 16 Market restraint relevance analysis (Current & future impact)
FIG. 17 Various ethical questions raised by gene therapy
FIG. 18 Recent and ongoing manufacturing capacity expansions for viral vector and large scale cell therapies, as of 2017
FIG. 19 Penetration & growth prospect mapping for vector type, 2017
FIG. 20 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 21 Porter’s Five Forces Analysis
FIG. 22 Viral vector & plasmid DNA manufacturing market: Vector type outlook key takeaways
FIG. 23 Global viral vector & plasmid DNA manufacturing market: Vector type movement analysis
FIG. 24 Global adenovirus market, 2014 - 2025 (USD Million)
FIG. 25 Global retrovirus market, 2014 - 2025 (USD Million)
FIG. 26 Global plasmid DNA market, 2014 - 2025 (USD Million)
FIG. 27 Global AAV market, 2014 - 2025 (USD Million)
FIG. 28 Global lentivirus market, 2014 - 2025 (USD Million)
FIG. 29 Global other vectors market, 2014 - 2025 (USD Million)
FIG. 30 Viral vector & plasmid DNA manufacturing market: Workflow outlook key takeaways
FIG. 31 Global viral vector & plasmid DNA manufacturing market: Workflow movement analysis
FIG. 32 Global upstream manufacturing market, 2014 - 2025 (USD Million)
FIG. 33 Global vector amplification & expansion market, 2014 - 2025 (USD Million)
FIG. 34 Global vector recovery/harvesting market, 2014 - 2025 (USD Million)
FIG. 35 Global downstream manufacturing market, 2014 - 2025 (USD Million)
FIG. 36 Global purification market, 2014 - 2025 (USD Million)
FIG. 37 Global fill-finish market, 2014 - 2025 (USD Million)
FIG. 38 Viral vector & plasmid DNA manufacturing market: Application outlook key takeaways
FIG. 39 Global viral vector & plasmid DNA manufacturing market: Application movement analysis
FIG. 40 Global viral vector & plasmid DNA manufacturing market for antisense, RNAi, & molecular therapy, 2014 - 2025 (USD Million)
FIG. 41 Strengths and weaknesses of viral vector vaccines
FIG. 42 Global viral vector & plasmid DNA manufacturing market for vaccinology, 2014 - 2025 (USD Million)
FIG. 43 Viral vector & plasmid DNA manufacturing market: End-use outlook key takeaways
FIG. 44 Global viral vector & plasmid DNA manufacturing market: End-use movement analysis
FIG. 45 Global viral vector & plasmid DNA manufacturing market for pharmaceutical and biopharmaceutical companies, 2014 - 2025 (USD Million)
FIG. 46 Global viral vector & plasmid DNA manufacturing market for research institutes, 2014 - 2025 (USD Million)
FIG. 47 Viral vector & plasmid DNA manufacturing market: Disease outlook key takeaways
FIG. 48 Global viral vector & plasmid DNA manufacturing market: Application movement analysis
FIG. 49 Global viral vector & plasmid DNA manufacturing market for cancer, 2014 - 2025 (USD Million)
FIG. 50 Global viral vector & plasmid DNA manufacturing market for genetic disorders, 2014 - 2025 (USD Million)
FIG. 51 Global viral vector & plasmid DNA manufacturing market for infectious diseases, 2014 - 2025 (USD Million)
FIG. 52 Global viral vector & plasmid DNA manufacturing market for other diseases, 2014 - 2025 (USD Million)
FIG. 53 Regional market place: Key takeaway
FIG. 54 Viral vector & plasmid DNA manufacturing market: Regional outlook, 2017 & 2025
FIG. 55 North America viral vector & plasmid DNA manufacturing market, 2014 - 2025 (USD Million)
FIG. 56 U.S. viral vector & plasmid DNA manufacturing market, 2014 - 2025 (USD Million)
FIG. 57 Canada viral vector & plasmid DNA manufacturing market, 2014 - 2025 (USD Million)
FIG. 58 Europe viral vector & plasmid DNA manufacturing market, 2014 - 2025 (USD Million)
FIG. 59 Germany viral vector & plasmid DNA manufacturing market, 2014 - 2025 (USD Million)
FIG. 60 U.K. viral vector & plasmid DNA manufacturing market, 2014 - 2025 (USD Million)
FIG. 61 Asia Pacific viral vector & plasmid DNA manufacturing market, 2014 - 2025 (USD Million)
FIG. 62 Japan viral vector & plasmid DNA manufacturing market, 2014 - 2025 (USD Million)
FIG. 63 China viral vector & plasmid DNA manufacturing market, 2014 - 2025 (USD Million)
FIG. 64 Latin America viral vector & plasmid DNA manufacturing market, 2014 - 2025 (USD Million)
FIG. 65 Brazil viral vector & plasmid DNA manufacturing market, 2014 - 2025 (USD Million)
FIG. 66 MEA viral vector & plasmid DNA manufacturing market, 2014 - 2025 (USD Million)
FIG. 67 South Africa viral vector & plasmid DNA manufacturing market, 2014 - 2025 (USD Million)
FIG. 68 List of companies with portfolio for vector-based therapeutic candidate
FIG. 69 List of vector manufacturers
FIG. 70 Strategy Framework
FIG. 71 Market Participation Categorization

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report